• In early February 2026, McKesson Corporation reported third-quarter 2025 results showing higher sales of US$106.16 billion and increased net income of US$1.19 billion versus the prior year, alongside continued share repurchases and a new universal shelf registration filing.
• The company’s stronger earnings per share from continuing operations and ongoing reduction in shares outstanding highlight management’s focus on improving per-share financial performance and maintaining financial flexibility.
• Next, we’ll examine how McKesson’s stronger-than-expected quarterly earnings performance may influence its existing investment narrative and future expectations.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

McKesson Investment Narrative Recap

To own McKesson, you generally need to believe in resilient prescription and specialty drug volumes supporting its large-scale distribution and services platform, while recognizing ongoing exposure to drug pricing and healthcare policy risk. The latest quarter’s better-than-expected results appear to reinforce the near term earnings catalyst from strong U.S. pharmaceutical volumes, without materially changing the overarching risk that regulatory pressure could still weigh on margins.

The most relevant recent announcement is McKesson’s universal shelf registration covering common stock, preferred stock, debt securities, and other instruments, which provides additional financial flexibility alongside its ongoing buybacks. For investors focused on catalysts like automation, specialty drug growth, and value added services, this broader access to capital markets may simply be another tool the company can use if needed, rather than a shift in its core investment case.

Yet investors should also be aware that increasing regulatory scrutiny on drug pricing could eventually...

McKesson's narrative projects $478.8 billion revenue and $5.3 billion earnings by 2028.

Uncover how McKesson's forecasts yield a $966.13 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Five individual fair value estimates from the Simply Wall St Community span roughly US$665 to US$1,481, showing just how far apart views on McKesson can be. Set against this, the key risk around future drug pricing and healthcare policy decisions may heavily influence how each of these investors thinks about the company’s longer term earnings power and resilience.

Explore 5 other fair value estimates on McKesson - why the stock might be worth 29% less than the current price!

Build Your Own McKesson Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your McKesson research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free McKesson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McKesson's overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 54 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.